Pharmaceuticals

A new partnership will integrate data from millions in India and the UAE, aiming to fix research bias and build more equitable AI-driven medicine.

Positive study results for Alvotech's Entyvio biosimilar could disrupt the IBD market, promising lower costs for a blockbuster chronic care treatment.

Pharmaceutical giant Fagron expands into packaging in Brazil and raw materials in Hungary, fortifying its end-to-end personalized medicine supply chain.

A new hybrid exhibition model connects global buyers with Asian smart medical innovators for an unprecedented four-month period, signaling a major shift.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

With its lead drug MOLBREEVI under FDA review, Savara's upcoming investor talks are a critical test of its path from clinical trials to market.

A simple nasal spray could offer immediate, broad protection against the flu. New landmark studies show how this antibody-based shield could revolutionize prevention.

Robot orders surged 6.6% in 2025, driven by food, electronics, and life sciences, marking a major shift away from traditional automotive dominance.

With a fresh capital infusion extending its runway into 2027, GRI Bio pushes ahead with promising clinical data for its IPF and autoimmune disease pipeline.

New preclinical data suggests Arcellx's CAR T therapy may offer a safer profile than rivals, potentially avoiding severe neurological side effects.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

With a 90% clinical trial failure rate, BullFrog AI is launching a new tool to help drugmakers make smarter, risk-balanced R&D decisions.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.